Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline

Abstract

This Clinical Practice Guideline was developed in accordance with the European Society for Medical Oncology (ESMO) standard operating procedures for Clinical Practice Guidelines development (http://www.esmo.org/Guidelines/ESMO-Guidelines-Methodology).

Keywords

• risk reduction
• hereditary breast and ovarian cancer syndromes
• BRCA
• ESMO Clinical Practice Guideline